Top 50 Biotech Startup Investors in Asia (July 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Qiming Venture Partners
VC Fund
|
74 | China, United States, Hong Kong | Series B, Series A, Series C | Health Care, Biotechnology, Medical | $5M–$134M |
|
HSG
VC Fund
|
43 | China, United States, Hong Kong | Series A, Series B, Series C | Health Care, Biotechnology, Software | $4.4M–$214M |
|
BioVenture
VC Fund
|
38 | China, United States, Hong Kong | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $3M–$73M |
|
Lilly Asia Ventures
VC Fund
|
33 | China, United States, Hong Kong | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $14M–$283M |
|
Med-Fine Capital
VC Fund
|
31 | China, Hong Kong, United States | Series A, Seed, Series B | Medical, Health Care, Biotechnology | $2.8M–$60M |
|
Frees Fund
VC Fund
|
29 | China, United States, Singapore | Series A, Seed, Angel | Artificial Intelligence, Health Care, Biotechnology | $425k–$35M |
|
Kaitai Capital
VC Fund
|
29 | China, United States, Singapore | Series A, Seed, Series B | Biotechnology, Health Care, Pharmaceutical | $1.4M–$57M |
|
Matrix Partners China
VC Fund
|
27 | China, United States, Singapore | Series A, Series B, Seed | Health Care, Biotechnology, Software | $1.6M–$113M |
|
Legend Capital
VC Fund
|
25 | China, United States, South Korea | Series B, Series A, Series C | Health Care, Medical, Biotechnology | $2.9M–$156M |
|
Seeds Capital
VC Fund
|
24 | Singapore, United States, Hong Kong | Seed, Series A | Biotechnology, Software, Health Care | $767k–$24M |
|
IDG Capital
VC Fund
|
23 | China, United States, India | Series A, Series B, Series C | Software, Internet, E-Commerce | $3M–$200M |
|
Sherpa Healthcare Partners
VC Fund
|
22 | China, United States, Kenya | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $2.8M–$156M |
|
Northern Light Venture Capital
VC Fund
|
20 | China, United States, South Korea | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $1.3M–$100M |
|
Linear Capital
VC Fund
|
20 | China, Singapore, Switzerland | Seed, Angel, Series A | Artificial Intelligence, Software, Manufacturing | $1.4M–$122M |
|
Mitsubishi UFJ Capital
VC Fund
|
20 | Japan, United States, Singapore | Series A, Series B | Information Technology, Software, Health Care | $1.2M–$269M |
|
UntroD Capital
VC Fund
|
19 | Japan, Singapore, Austria | Seed, Series A | Manufacturing, Biotechnology, Health Care | $772k–$241M |
|
Highlight Capital
VC Fund
|
19 | China, United States, South Korea | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $2.8M–$74M |
|
CDH Investments
VC Fund
|
19 | China, United States, Canada | Series A, Series B, Series C | Manufacturing, Biotechnology, Health Care | $7.1M–$300M |
|
Hillhouse Investment
VC Fund
|
18 | China, United States, Singapore | Series B, Series A, Series C | Biotechnology, Health Care, Software | $2.9M–$220M |
|
Longpan Investment
VC Fund
|
18 | China, United States, Cayman Islands | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $14M–$60M |
|
SMBC Venture Capital
VC Fund
|
18 | Japan, United States, Singapore | Series A, Series B | Information Technology, Software, Health Care | $2.3M–$269M |
|
TF Capital
VC Fund
|
18 | China, United States | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $7M–$1.4B |
|
Green Pine Capital Partners
VC Fund
|
18 | China, United States, Canada | Series A, Series B, Angel | Artificial Intelligence, Biotechnology, Health Care | $425k–$150M |
|
Shenzhen Capital Group
VC Fund
|
18 | China, United States, Japan | Series A, Series B, Series C | Manufacturing, Health Care, Software | $1.5M–$156M |
|
ANRI
VC Fund
|
18 | Japan, United States, India | Seed, Series A | Software, Health Care, Information Technology | $497k–$115M |
|
Delian Capital
VC Fund
|
17 | China, United States, France | Series A, Seed, Series B | Biotechnology, Health Care, Manufacturing | $1.5M–$50M |
|
Puhua Capital
VC Fund
|
17 | China, United Kingdom, United States | Series A, Series B, Seed | Health Care, Medical, Manufacturing | $1.4M–$112M |
|
Osaka University Venture Capital
VC Fund
|
16 | Japan | Seed, Series A | Biotechnology, Health Care, Manufacturing | $3M–$142M |
|
Pan-Lin Capital
VC Fund
|
16 | China, United States, Canada | Series A, Seed, Series B | Health Care, Biotechnology, Medical | $1.4k–$57M |
|
Gaorong Capital
VC Fund
|
16 | China, United States, Hong Kong | Series A, Series B, Seed | Information Technology, Software, Artificial Intelligence | $2.8M–$120M |
|
Fast Track Initiative, Inc.
VC Fund
|
16 | Japan, United States, United Kingdom | Series A, Series B, Seed | Health Care, Biotechnology, Medical | $1.2M–$184M |
|
Prox Ventures
VC Fund
|
15 | China, United States, United Kingdom | Seed, Series A | Medical, Biotechnology, Health Care | $1.9M–$28M |
|
Cowin Capital
VC Fund
|
15 | China, Hong Kong, United States | Series A, Series B, Seed | Manufacturing, Health Care, Biotechnology | $1.4M–$50M |
|
CD Capital
VC Fund
|
15 | China, United States | Series A, Series B, Seed | Health Care, Biotechnology, Medical Device | $1.4M–$34M |
|
Baidu Ventures
VC Fund
|
14 | China, United States, Singapore | Series A, Seed, Series B | Artificial Intelligence, Health Care, Biotechnology | $1.4M–$145M |
|
SDIC Venture Capital
VC Fund
|
14 | China, United States, Hong Kong | Series B, Series A, Series C | Manufacturing, Biotechnology, Electronics | $2.8M–$129M |
|
Addor Capital
VC Fund
|
13 | China, Hong Kong, Singapore | Series A, Series B, Seed | Manufacturing, Semiconductor, Electronics | $1.4k–$43M |
|
UTEC - The University of Tokyo Edge Capital Partners
VC Fund
|
13 | Japan, United States, India | Seed, Series A | Health Care, Biotechnology, Medical | $3.1M–$78M |
|
Beijing Huafang Investment
VC Fund
|
13 | China | Series A, Seed, Angel | Biotechnology, Medical, Biopharma | $13M–$28M |
|
BioTrack Capital
VC Fund
|
13 | China, United States, Singapore | Series A, Series B, Seed | Biotechnology, Health Care, Medical | $14M–$168M |
|
Shunwei Capital
VC Fund
|
13 | China, United States, India | Series A, Series B, Series C | Manufacturing, Software, Internet | $1.4M–$100M |
|
Lapam Capital
VC Fund
|
12 | China, United States | Series A, Series B, Series C | Biotechnology, Pharmaceutical, Health Care | $13M–$100M |
|
Hillhouse Ventures
VC Fund
|
12 | China, Singapore, Norway | Series A, Series B, Seed | Manufacturing, Biotechnology, Health Care | $10M–$120M |
|
Legend Star
VC Fund
|
12 | China, United States, France | Series A, Seed, Angel | Health Care, Medical, Robotics | $425k–$112M |
|
Keio Innovation Initiative
VC Fund
|
12 | Japan, United Kingdom | Series A, Seed | Health Care, Medical, Biotechnology | $1.5M–$64M |
|
Cowin Venture
VC Fund
|
12 | China, United States, Hong Kong | Series A, Angel, Series B | Health Care, Medical, Biotechnology | $425k–$257M |
|
K2VC
VC Fund
|
12 | China, United States, Japan | Series A, Seed, Angel | E-Commerce, Manufacturing, Biotechnology | $425k–$25M |
|
JAFCO
VC Fund
|
12 | Japan, United States, Israel | Series A, Series B | Information Technology, Software, Artificial Intelligence | $1.9M–$198M |
|
Oriental Fortune Capital
VC Fund
|
12 | China, United States | Series A, Series B, Seed | Software, Manufacturing, Information Technology | $1.4M–$100M |
|
Sinovation Ventures
VC Fund
|
11 | China, United States, Hong Kong | Series A, Seed, Series B | Software, Artificial Intelligence, Internet | $1M–$110M |
| Access all 50 investors in Asia Biotech startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companiesin the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 803
- Round size: Series A $5M–$68M; Series B $9.4M–$100M; Series C $14M–$134M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely still investing — raised $887M in 2023
Portfolio highlights
- Nice Tuan — Nice Tuan is an e-commerce platform that provides daily groceries and miscellaneous products.
- Twine Health — Fitbit Health Solutions' wellness and health solutions can help keep your population healthy and drive meaningful employee engagement. Learn more.
- WindMIL Therapeutics — WindMIL Therapeutics translates novel insights in bone marrow immunology into life-saving cell therapies for cancer patients. The company leveraging its proprietary platform to develop a novel class of cell therapies called MILs (Marrow Infiltrating Lymphocytes) derived from memory T cells found in the bone marrow. WindMIL Therapeutics wasestablished in 2015 and is based in Baltimore, MD.
We help founders build enduring companies.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Series A, Series B, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 751
- Round size: Series A $4.4M–$100M; Series B $12M–$200M; Series C $26M–$214M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- MarqVision — Effortlessly discover and remove counterfeits to protect your sales and reputation.
- Midas — Midas is the first neobroker of Turkey, providing zero commission Turkish and American stocks.
- Yunzhou Zhiwei — Yunzhou Zhiwei is a high-tech startup focused on serving large-scale equipment maintenance industries such as aviation, aerospace, shipbuilding, and rail transit. It leverages smart maintenance concepts and advanced digital technologies to make complex equipment maintenance more efficient and lean. The company drives industrial transformationtoward intelligent maintenance, helping enterprises enhance growth, efficiency, and operational excellence.
Suzhou Industrial Park Bioventure Investment Management Limited (Bioventure) was established in September 2013. Bioventure its first element of the new bio-industry funds 540 million yuan fund size. Bioventure specialize in the field of life sciences in the early stages of the venture capital investments as having high strength and growth, greaterdevelopment space, excellent management team, biotechnology, drug discovery, medical devices and healthcare services companies, and provide capital, management , operation and other aspects of post-investment support and services.Bioventure brought together senior investment professionals team with bio-pharmaceutical industry investment experience, strong fund management, entrepreneurship and venture capital and operating experience in business, have a deep understanding of the domestic and foreign markets, capable of its forward-looking international perspective and extensive The industry has the potential resources to help innovative companies grow rapidly and gain greater success, while giving fund investors bring considerable returns.Suzhou Industrial Park, the core investor BioBay has the country's best medical and pharmaceutical incubator function, use the platform, the project team has great resources and industrial service advantages, Yuan-sheng venture has successfully invested in 20 projects have been cast projects in their own development and follow-up financing, has made outstanding achievements in the industry for all to see, and won the Venture's trust and praise.By focusing and extensive industry resources, Bioventure determined to become one of China's most successful medical and pharmaceutical venture fund. Bioventure expectations and in the medical and pharmaceutical industry where there joint venture development cooperation.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 168
- Round size: Seed $7.1M–$41M; Series A $3.8M–$47M; Series B $3M–$73M
- Lead/follow: 36% lead, 64% follow
Portfolio highlights
- Dami&Xiaomi — Rice and millet is China's leading platform services for children with autism spectrum, from 2014 Nian 9 Yue Jiang Ying Shuang (rice) founded the "rice and millet" micro-channel public number. It now provides integrated services such as rehabilitation services, integrated education support, parent training, online courses, andpopular science information.
- CART Medical — CART Medical Technologies, Ltd. is a high-tech company specializing in the development and application of new technologies for immune cell therapy. It has a 2,200 square meter GMP laboratory and research and development laboratory.
- MyoGene Life Sciences — MyoGene Life Sciences is a regenerative medical company that specializes in the promotion of its regenerative repair material product line for bone repair.
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 217
- Round size: Series A $14M–$100M; Series B $25M–$110M; Series C $29M–$283M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — raised $40M in 2019
Portfolio highlights
- Passage Bio — Passage Bio, a genetic medicines company, is changing the future of CNS disorders and transforming the lives of patients and their families.
- ProfoundBio — ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.
- Tmunity Therapeutics — Tmunity Therapeutics is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), universal engineered T cell platforms, and Chimeric Antigen....
Med-Fine Capital is a venture capital firm focusing on early stage investments in China healthcare industry. The company is headquartered in Shanghai with offices in Beijing and Shenzhen.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 80
- Round size: Seed $8M–$60M; Series A $2.8M–$40M; Series B $11M–$60M
- Lead/follow: 30% lead, 70% follow
- Last fund: May invest from a new fund soon — raised $69M in 2019
Portfolio highlights
- Med-Vision — Virtual reality (VR) medical care service provider based in Hangzhou.
- Zhuanma Biotech — Zhuanma Biotechnology is a gene editing service provider dedicated to clinically developing effective ultra-small gene editors into genetic therapeutics that are "curable once and for all."
- Beijing Ansong Technology — Beijing Ansong Technology Co., Ltd. is an enterprise focusing on the research and development, production, and sales of orthopedic medical devices. The company cooperates with domestic and foreign universities, research institutes, and doctors in hospitals, and is committed to creating original orthopedic products with independent knowledgeproducts.Beijing Ansong Technology was founded on June 27, 2011 by Liang Tao in Fengtai, Beijing.
By adopting revolutionary mechanisms, FREES FUND is devoted to change the long-established rules in the venture capital. By leveraging the cutting-edge technologies and resources, FREES FUND aims at investing in great startups and helping them grow into great enterprises that are valuable to our society. We mainly invest in early-stagestartups, and hope to become their first-round institutional investor. Our primary interested areas are broad-sense TMT (Technology, Media, Telecom), B2B and deep technology.
Show more...Investment focus
- Industry: Artificial Intelligence, Health Care, Biotechnology
- Stage:Series A, Seed, Angel
- Geography: China, United States, Singapore
Investor stats
- Total investments: 213
- Round size: Seed $1.4M–$14M; Angel $425k–$17M; Series A $1.4M–$35M
- Lead/follow: 28% lead, 72% follow
- Last fund: May invest from a new fund soon — raised $130M in 2015
Portfolio highlights
- SoundAI — Sound Technology is a science and technology innovation company that specializes in acoustics frontier technology and artificial intelligence interaction. It is committed to lead the more interactive experience of artificial intelligence in the real environment and realize the human-computer interaction vision that "listen to you and know whatyou think".
- Methuselah — Methuselah is a research and development manufacturer of medical nutritional food.
- Jiajin Biotech — Jiajin Biotech is a pharmaceutical R&D service provider. It specializes in the development of antibody-small nucleic acid conjugates.
KAITAI CAPITAL, founded in 2009, is a professional investment management organization that mainly engaged in innovative investment, industrial investment, and wealth management business. Fields of investment include biopharma, healthcare services, agriculture tech, consumer business, digital technology and etc.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series A, Seed, Series B
- Geography: China, United States, Singapore
Investor stats
- Total investments: 131
- Round size: Seed $2.4M–$20M; Series A $1.4M–$35M; Series B $4.3M–$57M
- Lead/follow: 34% lead, 66% follow
Portfolio highlights
- Aoquan —
- Nafi Pharmaceuticals — Nafi Pharmaceuticals develops novel medications for central nervous system illnesses.
- Astrocyte Pharmaceuticals — Astrocyte Pharmaceuticals Inc. is a privately held drug development company dedicated to accelerating the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation, and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke,TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.
Matrix Partners China builds long-term relationships with entrepreneurs and helps them build significant, industry-leading companies.Since its inception in 1977, Matrix Partners China has made hundreds of investments and played an active role in the development of many successful businesses, 50 of which went on to IPO, and 75 of which have goneon to profitable M&A events. The firm consistently ranks in the top venture firms in terms of returns to its investors.Matrix Partners China combines local knowledge with global experience and vision. Its team consists of both former entrepreneurs and experienced investors. Its past successes include Focus Media, Eachnet, and Baidu, among others. The company invests across multiple sectors and stages.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Software
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 459
- Round size: Seed $1.6M–$32M; Series A $2.9M–$57M; Series B $10M–$113M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- TT Yuyin — Quwan provides services including instant voice messaging, social gaming, esports, and game distribution. It operates TT Voice, which started as a voice chat application designed for mobile gamers and was later developed into a social gaming platform. It focuses on developing personalized services for the Gen Z audience.
- Huangbaoche — Huangbaoche is a travel service providing tour packages and booking services. Huangbaoche has over 100,000 Chinese-speaking drivers and tour guides providing airport pick-up services, chartered car services, and guided tours in over 1,500 overseas travel destination cities in 80 countries.
- Jiajin Biotech — Jiajin Biotech is a pharmaceutical R&D service provider. It specializes in the development of antibody-small nucleic acid conjugates.
Legend Capital, a subsidiary of Legend Holdings Ltd., started its vintage year in April, 2001 with a mission to become a top-notch and the most respected venture capital investment manager in China.Managing up to US$700 million across four funds, Legend Capital focuses on driving high-growth ventures with operations substantially based in Chinaor on markets related to China.Legend Capital mainly invests in early stage IT companies, specifically, in sectors of network applications and services, outsourcing and professional services, Infrastructure (IC design/key components), and mid-market growth stage companies in the fields of consumer goods, clean technology, health care, equipment manufacturing and modern services.Among over 60 portfolio companies are Joyo.com (acquired by Amazon.com), SinoCom (0299.HK), Solarfun Power (Nasdaq: SOLF), Spreadtrum Communications (Nasdaq: SPRD), China Sunshine Paper (2002.HK), and VanceInfo (NYSE:VIT), Eyang (0117.HK), etc.As an active investor, Legend Capital provides its portfolio companies extensive business resources and tailored services to assist with business development, company image building, and other critical company building activities on Chinese market so as to add value and maximize returns. Legend Capital is proud and thankful that it has the opportunity to blaze a trail with its innovative practice for China's venture capital industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series B, Series A, Series C
- Geography: China, United States, South Korea
Investor stats
- Total investments: 409
- Round size: Series A $2.9M–$93M; Series B $12M–$115M; Series C $14M–$156M
- Lead/follow: 39% lead, 61% follow
- Last fund: Likely still investing — raised $177M in 2021
Portfolio highlights
- Pony.ai — Pony.ai is a startup that builds full-stack autonomous driving solutions. It is a pioneer in autonomous mobility technologies and services across the US and China, spearheading public-facing Robotaxi pilots in both markets. Pony.ai is committed to creating a safe and sustainable mobility future by delivering autonomous mobility everywhere.Thecompany was founded by James Peng and Tiancheng Lou in 2016 and is headquartered in Fremont, California, United States.
- Huixin Bio — Huixin Bio is a developer of exosome purification products and early cancer detection technology.
- QANDA(Mathpresso) — Providing the most effective education for all - We build QANDA, the world's leading personalized learning platform.
Catalysing smart monies into Singapore-based, early-stage technology startups.
Show more...Investment focus
- Industry: Biotechnology, Software, Health Care
- Stage:Seed, Series A
- Geography: Singapore, United States, Hong Kong
Investor stats
- Total investments: 142
- Round size: Seed $767k–$6M; Series A $3.5M–$24M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- HealthBeats — HealthBeats is a product based on their belief,regular monitoring outside of healthcare settings will only lead to better results.
- ChemT Biotechnology — The goal of ChemT Biotechnology is to increase patient access to the most cutting-edge biologics, beginning with the urgent issues in manufacturing and research and development.
- Protuoso Biosciences — Protuoso Biosciences is a biotechnology company developing next-generation multifunctional biologics designed to address complex disease biology.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!IDG Capital is a global investment firm partnering with founders to build enduring businesses through capital, expertise, and long-term support.
Show more...Investment focus
- Industry: Software, Internet, E-Commerce
- Stage:Series A, Series B, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 750
- Round size: Series A $3M–$122M; Series B $8.3M–$141M; Series C $15M–$200M
- Lead/follow: 34% lead, 66% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- Jumeng — Jumeng is a developer of a logistic service platform. The company based in Shanghai, China.
- HT Aero — HT Aero aspires to be the pioneer of urban air mobility (UAM) and is dedicated to producing safe and intelligent electric flying vehicles. which combine automotive and aerospace technologies to realize domestic air-travel usage at scale.
- Fenbeitong — Fenbeitong is the enterprise consumption platform for full process control. Through intelligent control rules and reminding measures, Debeitong helps enterprises to save a lot of money during travel, car use, procurement and other public consumption. Through the credit monthly payment and unified invoice consumption mode, Debeitong helps employeesto spare money. , free of charge, no reimbursement, greatly improve the efficiency of business operations.
Sherpa Venture Capital is an investment firm that focuses on the investment and cultivation of the Pharmaceutical and Biotech industry. It also specializes in the investment and management of sector leaders and innovators within the Pharma, GeneTech, MedTech, Medical services, and various sub-sectors, where they have established robust portfoliosources, lasting value-adding cooperations and relationships, as well as mature all-cycle services with key resources. It was founded in 2018 and is headquartered in Beijing, China.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, Kenya
Investor stats
- Total investments: 100
- Round size: Series A $2.8M–$50M; Series B $15M–$100M; Series C $12M–$156M
- Lead/follow: 29% lead, 71% follow
- Last fund: Likely still investing — fund raised in 2021
Portfolio highlights
- Yosemite Clinic — Yosemite Clinic is a full-service clinic providing convenient walk-in medical services in a state-of-the-art environment in Central Pudong. They offer family medicine, internal medicine, surgery, orthopedics (sports medicine), dermatology, medical cosmetology, dentistry, gynecology, pediatrics, ophthalmology, anesthesiology, rehabilitationmedicine, medical imaging, laboratory, pharmacy and more. Their onsite facilities and equipment include CT, X-ray, Ultrasound, Laboratory and Operating Rooms. Their doctors come from China and across the world, enabling us to serve you in many languages including, English, Japanese, Malay, Mandarin Chinese and Cantonese.
- Archimedes Vascular — Archimedes Vascular operates as a medical device company, that treat patients with severe hypertension.
- Biortus — Wuxi Biortus Biosciences is an innovation-driven contract research organization (CRO) committed to high-quality R&D services in support of drug discovery.To help our clients achieve their drug discovery goals, we have established five world-class research platforms. These are Recombinant Protein Production, Structural Biology (X-rayCrystallography and Cryo-EM), In Vitro Assays and Screening, Medicinal Chemistry, and Process Development. Through the years, our R&D team has developed a number of practical and innovative techniques of which some have already been granted patent.
Supporting the next generation of entpreneurs in enterprise, healthcare, and consumer with disruptive potential.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, South Korea
Investor stats
- Total investments: 244
- Round size: Seed $1.3M–$100M; Series A $4.3M–$52M; Series B $11M–$62M
- Lead/follow: 28% lead, 72% follow
- Last fund: Likely still investing — raised $375M in 2021
Portfolio highlights
- Flytech — Flytech specializes in crystal materials and related components for magneto-optical-electrical integrated signal processing.
- Moge Microflow — Moge Microflow is a manufacturer of equipment for microreactors. It provides continuous flow production technologies and equipment for nanomaterials, pharmaceutical intermediates, and fine chemicals, as well as standardized high-end microreactor equipment.
- Bianzhong New Materials — Bianzhong New Materials is a high-tech company that specializes in the research and development of equipment for weaving and shaping three-dimensional preforms of high-strength fiber composite materials.
Linear Capital is a Frontier Tech Fund founded in 2014 by Harry Wang, Facebook's first Chinese R&D manager. We currently manage 10 funds with AUM of more than $2 billion.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Manufacturing
- Stage:Seed, Angel, Series A
- Geography: China, Singapore, Switzerland
Investor stats
- Total investments: 91
- Round size: Seed $1.4M–$122M; Angel $1.4M–$122M; Series A $5.7M–$50M
- Lead/follow: 31% lead, 69% follow
- Last fund: Likely still investing — raised $500M in 2021
Portfolio highlights
- Pacdora — Pacdora is an incredibly user-friendly online mockup design platform that boasts an extensive collection of 3D mockups and box templates. Whether you're a seasoned designer or just starting out, you can effortlessly create eye-catching mockups in no time. Plus, with our powerful 3D modeling software and a suite of AI design assistant tools atyour fingertips, your creative possibilities are limitless. Unleash your imagination with Pacdora today!
- Rino — L4 autonomous delivery vehicles by Rino.ai serve logistics, retail, and cold chain needs across 100+ cities. Revolutionize your logistics with Autonomous Delivery Vehicles, offering a safe, efficient, and eco-friendly solution for last-mile delivery in urban and rural settings.
- ACXEL Tech — ACXEL Tech develops large area electronics have given us flat panel displays and flexible, wearable devices. ACXEL takes these ‘active’ pixels and puts them to work transporting liquid droplets – precisely and at amazing speed.Millions of pixels are transformed into tiny engines moving samples around via a high throughput, low cost andprogrammable platform, offering a wide range of possibilities in chemistry, biology and medtech.
Mitsubishi UFJ Capital is a venture capital firm focusing on life science, ICT, and high technology investments.
Show more...Investment focus
- Industry: Information Technology, Software, Health Care
- Stage:Series A, Series B
- Geography: Japan, United States, Singapore
Investor stats
- Total investments: 549
- Round size: Series A $1.2M–$86M; Series B $4.2M–$269M
- Lead/follow: 5% lead, 95% follow
- Last fund: May invest from a new fund soon — raised $1.4B in 2020
Portfolio highlights
- Caguuu — Caguuu offers high-quality designer furniture at affordable prices, through e-commerce, eliminating middlemen and store operating costs.
- Diggle — DIGGLE is a service that provides fundamental management accounting management on the cloud called fraud management. It is possible to reduce the mistakes and man-hours of the fraud management task and easily carry out the fraud management task even if it is not an expert in finance or accounting.DIGGLE covers budget creation work and budgetrecord comparison work, especially in the foreman management work. In the budget creation work, the KPI and the budget are automatically created by inputting the target numerical value to the preset parameters utilizing the budget generator function, while the forecast contrasting work is made up of the financial information, non-financial information It is easy to calculate by simply entering the numerical value, and it is possible to carry out calculation of the forecast contrast.
- Instalimb — Instalimb is the world's first 3D printing prosthesis business.
UntroD Capital is an R&D-based innovative technology that specializes in social implementation.
Show more...Investment focus
- Industry: Manufacturing, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: Japan, Singapore, Austria
Investor stats
- Total investments: 130
- Round size: Seed $772k–$43M; Series A $2.1M–$241M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- CastBio — Castbio specializes in antibody-drug conjugate-based drug discovery research and development. Along with medications, it also creates research reagents, medical equipment, in vitro diagnostic items, and offers drug discovery consulting.
- 3DC — 3DC develops and manufactures a new carbon material, graphene meso sponge (GMS), for electrodes in next-generation batteries, capacitors, fuel cells and other energy storage and generation devices.
- Formas.AI — Formas.AI is a multi-modal, AI-powered design platform specifically built for architects, designers, and educators to generate and visualize creative architectural concepts.
Highlight Capital is an investment firm dedicated to support healthcare companies to generate robust and sustained growth prospect.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, South Korea
Investor stats
- Total investments: 165
- Round size: Seed $10M–$73M; Series A $2.8M–$74M; Series B $7.6M–$70M
- Lead/follow: 36% lead, 64% follow
- Last fund: Likely still investing — raised $563M in 2021
Portfolio highlights
- Yushi Space — Yushi Space is a liquid rocket developer that focuses on the development and manufacture of large-capacity, low-cost and rapidly reusable liquid rockets.
- Approaching.AI — Approaching.AI is an AI Infra company focusing on the important large model application scenarios such as RAG.
- Xingneng Xuanguang — Xingneng Xuanguang is a fusion energy company that specializes in the development of advanced field reverse magnetic mirror fusion path technology.
CDH Investments is an international alternative asset fund manager with over $27 billion of assets under management. CDH Investments was established in 2002 by the former private equity group of China International Capital Corporation and is managed by an experienced team of senior private equity professionals who have worked together for manyyears focusing all their professional time on investing in China. CDH has consistently delivered superior returns relative to industry peers and is well positioned to continue to generate superior returns due to the team's proven investment experience and expertise investing in China.
Show more...Investment focus
- Industry: Manufacturing, Biotechnology, Health Care
- Stage:Series A, Series B, Series C
- Geography: China, United States, Canada
Investor stats
- Total investments: 284
- Round size: Series A $7.1M–$100M; Series B $14M–$142M; Series C $14M–$300M
- Lead/follow: 46% lead, 54% follow
Portfolio highlights
- ThreatBook — ThreatBook delivers high-fidelity cyber threat intelligence, detection and response rooted in APAC, trusted worldwide. See what others miss. Act with clarity. Stay ahead of risk.
- Ai Ma Biology — Ai Ma Biology is a small RNA nucleic acid drug developer, dedicated to the transformation of achievements in the field of biosynthesis.
- Eyegood Ophthalmic Hospital — Eyegood Ophthalmic Hospital is a ophthalmology hospital.
Founded in 2005, Hillhouse is a leading global investment management firm, active across public equity, private equity, real estate and private credit. The firm invests over a long-term horizon and partners with exceptional entrepreneurs to deliver sustainable value creation for quality companies.Hillhouse is a full life-cycle private equityfirm, investing for the long term across opportunities in the healthcare, business services, consumer, and industrials sectors. The firm manages capital on behalf of global institutions such as non-profit foundations, endowments, and pensions.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series B, Series A, Series C
- Geography: China, United States, Singapore
Investor stats
- Total investments: 331
- Round size: Series A $2.9M–$142M; Series B $14M–$219M; Series C $15M–$220M
- Lead/follow: 38% lead, 62% follow
- Last fund: May invest from a new fund soon — raised $11B in 2018
Portfolio highlights
- Sainte — Sainte is a company which provides professional nutritional solutions for babies with different nutritional needs
- Vita Dynamics — Vita Dynamics involves learning through real-world interactions by developing robots that can physically engage with their environment, they can adapt more naturally and efficiently.
- NeueHCT — Horizon Continental Technology is a joint venture between Continental Group and Horizon Robotics
Longpan Investment is an investment firm.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Cayman Islands
Investor stats
- Total investments: 39
- Round size: Seed $14M–$60M; Series A $14M–$30M; Series B $14M–$37M
- Lead/follow: 54% lead, 46% follow
Portfolio highlights
- Bodie Hekang — Bodie Hekang is a biopharmaceutical services company dedicated to advancing therapies for autoimmune and inflammatory diseases. Combining translational research, preclinical development, and clinical support, the company specializes in engineering and developing regulatory T cell (Treg) immunotherapies designed to restore immune tolerance andreduce pathological inflammation. Bodie Hekang partners with academic institutions, biotech firms, and pharmaceutical companies to provide end-to-end services that include target validation, cell manufacturing process development, potency and safety testing, and regulatory strategy support. Its multidisciplinary team of immunologists, cell biologists, and clinical development experts focuses on innovative approaches to enhance Treg stability, specificity, and functionality, aiming to translate promising laboratory findings into scalable, clinically viable treatments for conditions such as rheumatoid arthritis, inflammatory bowel disease, and systemic lupus erythematosus.
- Maibozhixing —
- Qinghui Liannuo — Qinghui Liannuo is a scientific and technological innovation enterprise that transforms Tsinghua University's achievements in the research and development and application of immunotherapy technology. Actively promote the development of the γδ-T cell immunotherapy industry. Committed to bringing good news to patients with refractory andrecurrent solid tumors and hematomas.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Sumitomo Mitsui Banking Corporation (SMBC) and its group companies offer a broad range of financial services centered on banking. They are also engaged in the leasing, securities, credit card, investment, mortgage securitization, venture capital and other credit related businesses. The following lists the activities of SMBC, its subsidiaries andaffiliates in the various business segments.
Show more...Investment focus
- Industry: Information Technology, Software, Health Care
- Stage:Series A, Series B
- Geography: Japan, United States, Singapore
Investor stats
- Total investments: 553
- Round size: Series A $2.3M–$128M; Series B $3.2M–$269M
- Lead/follow: 4% lead, 96% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Fermelanta — Fermelanta produces rare plant-based ingredients through microbial fermentation. It engineers a cell to build a biosynthetic pathway of target molecules with gene transfer and disruption.
- Atom — Atom is a humanoid robot built platform. Its bipedal, dual-armed robots are designed not just as industrial tools but as collaborators that expand human capability. By combining advanced Physical AI—environmental perception, judgment, and action planning—with robust robotic hardware, Atom is creating adaptive agents capable of working acrossdiverse settings to augment or, where appropriate, replace human labor. The company positions these robots as a next step in societal evolution: a new class of machines that learn and behave in human-like ways to advance productivity, safety, and quality of life.
- Link Therapeutics — Link Therapeutics specializes in developing therapeutic methods for targeting autoantibodies and identifying pathogenic autoantibodies.
TF Capital is a proprietary trading company that specializes in foreign exchange and invests in early stage ventures.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States
Investor stats
- Total investments: 63
- Round size: Series A $10M–$120M; Series B $11M–$110M; Series C $7M–$1.4B
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- QL Biopharma — QL Biopharma focuses on developing innovative drugs and premium me-too drugs targeting metabolic diseases.
- Vivatides Therapeutics — Vivatides Therapeutics develops new RNA treatments to help improve patients' lives using biotechnology research.
- Angitia Biopharmaceuticals — Angitia Biopharmaceuticals is a global biotechnology company focusing on the discovery and development of innovative therapeutics for serious musculoskeletal diseases.
Shenzhen Green Pine Capital Partners Co. Ltd. (“GPCP”) was established in 2007, with the investment team assembled in 2000. GPCP is one of the most time-honored Chinese VC companies that boast experience in areas such as biotech, new materials, new resources and AI, etc. Currently, GPCP manages assets over 15 billion RMB through 21 special fundsand have invested 7 billion RMB into 388 enterprises among which 14 are listed on NEEQ and 48 of them are either listed or acquired by listed companies, including BGI(300676.SZ), Aurora(600666.SH), Nationz Tech(300077.SZ), Foresee(002530.SZ), Qudian(NASDAQ:QD), etc. GPCP invested in the angel round of BGI (Beijing Genomics Institute), Royole, Kuang-Chi, Appotronics, BMF, C-one, Arrayed Materials and other star enterprises.GPCP is based in Shenzhen, with branches in Beijing, Shanghai and Guangzhou. GPCP also runs two GPI incubators and an incubator for overseas Chinese scientists who start businesses in China.
Show more...Investment focus
- Industry: Artificial Intelligence, Biotechnology, Health Care
- Stage:Series A, Series B, Angel
- Geography: China, United States, Canada
Investor stats
- Total investments: 190
- Round size: Angel $425k–$2.9M; Series A $1.4M–$92M; Series B $9.9M–$150M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — raised $138M in 2019
Portfolio highlights
- Enrikenuo — Enrikenuo is a biotechnology company that focuses on the research and development of new generation CAR-NK technology based cell drugs.
- Sungen Biomedical — Sungen Biomedical is engaged in the development of first-in-class (FIC) antibody therapeutics.
- Signet Therapeutics — Signet Therapeutics is a cutting-edge firm that conducts research and development on cancer-targeted drugs using AI and organoid disease models.
Shenzhen Capital Group Co., Ltd (“SCGC”) is a limited venture capital company established by the Shenzhen Government in 1999. Since its establishment, SCGC has focused on cultivating national industries, shaping national brands, promoting economic transformation, and emerging industries developing. SCGC has registered capital of 5.42 billion RMB,and a total AUM of 338.99 billion RMB. SCGC primarily invests in SMEs, innovative high-tech enterprises, enterprises in emerging industries, and enterprises in start-up period, growth period and in transformation, covering industries supported by national policies, including IT, internet, new media, biopharma, new energy, environmental protection, chemical engineering, new material, high-end equipment manufacturing, consumption goods, modern service, etc. By the end of April 2019, SCGC ranked the first based on the number of portfolio companies and the number of listed portfolio companies: 994 portfolio companies, investments totaling 43.9 billion RMB, 145 of which have been listed in 16 capital markets worldwide.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Software
- Stage:Series A, Series B, Series C
- Geography: China, United States, Japan
Investor stats
- Total investments: 485
- Round size: Series A $1.5M–$156M; Series B $14M–$142M; Series C $4.3M–$142M
- Lead/follow: 40% lead, 60% follow
Portfolio highlights
- Prosemi — Pusenmei is a precision micro-resistance current sensor developer company committed to delivering professional and diverse precision micro-resistance current detecting resistors and circuit protection solutions.
- Enrikenuo — Enrikenuo is a biotechnology company that focuses on the research and development of new generation CAR-NK technology based cell drugs.
- Waker Biology — Weike Bio is a gene therapy drug development company.
ANRI is a Japanese venture capital firm that mainly invests in seed and early-stage startups.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Series A
- Geography: Japan, United States, India
Investor stats
- Total investments: 258
- Round size: Seed $497k–$41M; Series A $2.4M–$115M
- Lead/follow: 23% lead, 77% follow
- Last fund: Likely still investing — raised $102M in 2022
Portfolio highlights
- Tacoms — CAMEL is a service that allows you to easily manage orders from multiple food delivery / takeout services on a single tablet.
- Any Style —
- Smile Robotics — Smile Robotics provides Service Robots in Japan.
Founded in 2011, Delian Capital specializes in the field of tech-driven industry such as high-end manufacturing, cutting-edge technologies, and healthcare. Their investments range from robotics, Smart manufacturing Semiconductor, AI, big data, enterpriseservices, healthcare, etc.Examples of their investment portfolio: YueBoo、Hunan zhongli、Esafenet、Venus MedTech、MicuRx、Rokae、 IMI、12 Sigma Technologies.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Manufacturing
- Stage:Series A, Seed, Series B
- Geography: China, United States, France
Investor stats
- Total investments: 97
- Round size: Seed $1.5M–$50M; Series A $1.6M–$17M; Series B $9.9M–$29M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- BCI-Sonics — BCI-Sonics is an innovative medtech company developing non-invasive brain-computer interface solutions using advanced transcranial focused ultrasound (tFUS) technology. The company builds a next-generation therapeutic platform enabling precise neuromodulation to treat central nervous system disorders. BCI-Sonics develops low-intensity focusedultrasound technology that non-invasively stimulates deep brain regions with high precision. They combine ultrasound engineering and neuroscience to interface safely and effectively with the human brain without surgery. The company is creating an AI ultrasound brain-computer interface platform for therapeutic neuromodulation applications.
- Genrobot.ai — Genrobot.ai develops AI-powered robots for automation, data analysis, and intelligent task management across industries.
- Gnosis Healthineer — Gnosis Healthineer provides medical devices to hospitals such as Clinical EEG AI Model. It builds an EEG data center for second- and third-level general hospitals to solve the problem of insufficient EEG data storage. The hardware construction of the data center includes: PB-level storage and servers, and high-performance computing equipment.
Puhua Capital is an equity investment firm that focuses on early and middle project. Puhua Capital provides the required resources and management experience for the invested enterprise, investing funds and more resources and wisdom. Puhua Capital has invested nearly 300 excellent start-ups.
Show more...Investment focus
- Industry: Health Care, Medical, Manufacturing
- Stage:Series A, Series B, Seed
- Geography: China, United Kingdom, United States
Investor stats
- Total investments: 235
- Round size: Seed $1.4M–$29M; Series A $1.4M–$112M; Series B $2.8M–$103M
- Lead/follow: 36% lead, 64% follow
Portfolio highlights
- Nuoyun Drive —
- Zhongke Guosheng — Zhongke Guosheng is a bio-based materials R&D firm that designs and develops furan-based bio-based materials.
- Interstellar Lightyear — Interstellar Lightyear Technology is a developer specializing in dexterous robotic hands, focusing on creating intelligent dexterous hands with advanced capabilities for precise manipulation.
Osaka University Venture Capital is a venture capital firm that focuses on early-stage ventures in the fields of life innovation, green innovation, and platform technology. The firm was founded in 2014 and based in Osaka, Japan.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Manufacturing
- Stage:Seed, Series A
- Geography: Japan
Investor stats
- Total investments: 83
- Round size: Seed $4.5M–$50M; Series A $3M–$142M
- Lead/follow: 34% lead, 66% follow
Portfolio highlights
- JiMED — JiMED designs & develops AI based brain-computer interface for implant in ALS patients to improve communication.
- LQUOM — QWAVE offers cryptography communication technology.
- Toregem BioPharma — Toregem BioPharma is a startup from Kyoto University that develops a treatment for congenital adentia. Toregem BioPharma is headquartered in Kyoto, Japan.
Panlin Capital, following the investment theme of ‘consumption upgrade driven by technology innovation’, targets the start-ups which are specialized in biotechnology and data intelligence sectors.As a venture capital corporation, Panlin Capital has became professional as well as influential in the biotechnology and data intelligence sectors.Identify the entrepreneurs among scientists.Enable the innovators among entrepreneurs。
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Seed, Series B
- Geography: China, United States, Canada
Investor stats
- Total investments: 81
- Round size: Seed $1.4k–$28M; Series A $297k–$35M; Series B $7.1M–$57M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Aerofugia — Aerofugia is a technology company with low-altitude travel and vehicle-mounted flight as its core, and a practitioner of the new general aviation strategy under Geely Technology Group.
- Lingdong Core Optics — Lingdong Core Optics is a high-tech firm that specializes in the design and implementation of silicon-based integrated optoelectronic chips.
- UniXell Biotechnology — Yuesai Biotechnology is a new-generation cell therapy drug developer, focusing on the development of a new generation of cell therapy drugs.
Gaorong Capital is a venture capital firm that focuses on early and growth stage investments in TMT, including AI and frontier technologies.
Show more...Investment focus
- Industry: Information Technology, Software, Artificial Intelligence
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 278
- Round size: Seed $2.8M–$57M; Series A $2.8M–$71M; Series B $14M–$120M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $1.2B in 2020
Portfolio highlights
- GravityXR — GravityXR is an XR chip developer and a terminal equipment manufacturer serving the XR (AR/VR/MR) field, providing chip platforms for virtual reality, augmented reality and mixed reality as well as supporting hardware solutions, including platforms A complete set of technical services including software and technology suites includingapplication interfaces, key component selection, product prototype development support, etc.
- AIpark — AIpark is provides a smart parking management solution. AIPark upgrades traditional parking spaces into “smarter ones” for local governments or businesses by leveraging on its in-house visual recognition technologies.
- Danke Apartment — Danke Apartment (蛋壳公寓) is a leading internet enabled apartment management startup in China. Founded in Jan 2015, Danke is managing over 320K apartment units in Beijing, Shanghai, Shenzhen, Hangzhou, etc
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Fast Track Initiative is a venture capital firm with an exclusive focus on life sciences and healthcare services.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Seed
- Geography: Japan, United States, United Kingdom
Investor stats
- Total investments: 81
- Round size: Seed $1.2M–$117M; Series A $1.5M–$113M; Series B $7.7M–$184M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $1.1B in 2021
Portfolio highlights
- NovAccel — NovAccel operates as a deep tech company, ensure a stable supply of medical radioisotopes.
- Sonire Therapeutics — Sonire Therapeutics provides High-Intensity Focused Ultrasound treatment for cancer.
- Neusignal Therapeutics — Neusignal Therapeutics is a medical company that develops therapeutic medicines for dementia and psychiatric illnesses.
Proxima Ventures focuses in the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential.They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Their team members with multidisciplinary backgrounds and resourceful networks, have many yearsof remarkable venture capital experience and achievements. They believe that active and effective collaboration with entrepreneurs will make substantial economic returns while bring meaningful improvements in public health.
Show more...Investment focus
- Industry: Medical, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: China, United States, United Kingdom
Investor stats
- Total investments: 79
- Round size: Seed $1.9M–$5.6M; Series A $2.8M–$28M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Shengxin Medical — Shengxin Medical is a cardiovascular interventional medical device developer, dedicated to creating innovative, high-quality solutions that improve the diagnosis, treatment, and management of cardiovascular diseases, while advancing minimally invasive medical technologies to enhance patient outcomes and clinical efficiency.
- Bluesail Surgical — Bluesail Surgical is a surgical device company that specializes in the development of innovative surgical instruments for cardiovascular and cerebrovascular treatments.
- Kingsung Medical Group — Kingsung Medical Group operates under the Mission “Simplify Surgery, Beautiful Life,” with its innovation centered on four core technology platforms at its Tianjin base: Mechanical Design, Polymer Materials, Biodegradable Magnesium Alloys, and Collagen Biomaterials. These platforms have enabled the development of pioneering medical devices,including microvascular anastomosis devices and neural tube. In particular, the Group’s biodegradable magnesium alloy technology is spearheading the advancement of next-generation orthopedic implants. Kingsung’s technological capabilities are evidenced by a portfolio of over 190 patents and its recognition as a National Key Enterprise. The Group also actively contributes to the industry as a standing council member of the Microsurgery Branch of the China Association of Medical Devices Industry and a member of the Chinese Society for Biomaterials.
Cowin Capital is a private placement equity investment company focusing on investing in a pioneering enterprise on a long-term basis. It has 18 years of experience in capital management, whose capital management scale was among the front rank, which invested more than 300 companies, of which 60 more became public companies, and 150 moresuccessfully exit.The company was successfully listed on NEEQ, with code 832793, as the third listed famous domestic venture capital institution in NEEQ. It is committed to supporting the growth of small and medium enterprises, continue to launch high-quality listed companies in China Capital Market.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 304
- Round size: Seed $1.4M–$20M; Series A $4.3M–$41M; Series B $2.8M–$50M
- Lead/follow: 47% lead, 53% follow
- Last fund: May invest from a new fund soon — raised $75M in 2014
Portfolio highlights
- QYSEA — QYSEA FIFISH 4K underwater video camera is combined with the world's advanced techniques, supports 20-megapixel photos shooting in various conditions. QYSEA underwater ROV drone with great durability & design. QYSEA - professional underwater drone manufacturer!
- Digital China — Digital China is a robotics company focused on developing humanoid interactive robots that can break traditional boundaries and create emotionally resonated partners.
- Yinli Electric — Ningxia Yinli Electric Co., Ltd. is mainly engaged in the production and research and development of reactors and transformers. At present, the company's main products include: three-phase filter reactors, four-phase five-column reactors, water-cooled reactors, three-phase AC reactors, hollow core Reactors, isolation transformers andhigh-frequency transformers, etc.
CD Capital is a venture capital firm specialized in life sciences and medical technology. They are currently managing both RMB and USD funds with total size of $600M. CD Capital is operated by a professional team with diversified and profound industry backgrounds. They have made over 40 investments with high growth potential and earned a reputationas a premier venture capital firm with main focus on China healthcare industry. With broad network around China and the world, they have been able to seize the global trend, capture investment opportunities as well as help to define the future for China healthcare industry. Ultimately, they strive to grow best-in-class companies and deliver solid financial return to their investors.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Series B, Seed
- Geography: China, United States
Investor stats
- Total investments: 70
- Round size: Seed $1.4M–$15M; Series A $1.4M–$32M; Series B $7.1M–$34M
- Lead/follow: 39% lead, 61% follow
Portfolio highlights
- Genlight — Genlight develops innovative treatment solutions for epilepsy and other neurological diseases. Genlight is headquartered in Hangzhou, China.
- Pipi Bear —
- Senas Medical — Senas Medical focuses on innovative cardiac electrophysiology solutions.
Doma Protocol is a purpose-built blockchain to modernize and unlock the liquidity of over 362M existing and future domains
Show more...Investment focus
- Industry: Artificial Intelligence, Health Care, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: China, United States, Singapore
Investor stats
- Total investments: 220
- Round size: Seed $1.9M–$14M; Series A $1.4M–$43M; Series B $8M–$145M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- Vesper — Vesper is an electrical and electronic manufacturing company that specializes in microphones, piezoelectric, and audio. The company is driven by a mission is to deliver voice-powered products to every market, around the world. Vesper was founded in 2009 and headquartered in Boston, Massachusetts.
- Automation Hero — Reduce your company's document processing time with an intelligent automation platform that's simple, secure, and accurate.
- Deepin Technology — Deepin Technology is a company that utilizes artificial intelligence, quantum chemistry, and high-throughput experiment technologies to enhance the efficiency and workflow of chemical material innovation. it offers efficient R&D solutions for chemical materials, aiming to solve lab bottlenecks, promote innovative research, and enhance customervalue.
ounded in 2016, SDIC Venture Capital Co., Ltd. (SDICVC) is a fund management company founded by the State Development and Investment Corp. (SDIC), under a market driven governance structure. SDICVC currently manages four funds, with total asset under management at RMB 14 Billion.SDICVC puts into practice the marketization and industrializationof the nation’s scientific and technological achievements, focusing on an investment strategy of "serving the national innovation strategy and focusing on the transformation of scientific and technological achievements". SDICVC puts its expertise and experience to work to achieve its goals of policy orientation and return on investment, faithfully implementing the national development strategy, striving to realize the synergy between the government, the society and the market, realizing its positioning as "an ideal, trustworthy, respected, influential partner” and its role as a leading professional venture fund management institution.
Show more...Investment focus
- Industry: Manufacturing, Biotechnology, Electronics
- Stage:Series B, Series A, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 164
- Round size: Series A $8.5M–$97M; Series B $2.8M–$129M; Series C $14M–$58M
- Lead/follow: 54% lead, 46% follow
- Last fund: May invest from a new fund soon — last raise in 2018
Portfolio highlights
- Parylene — Parylene is a provider of protective coating application solutions
- Alnan Aluminium — Alnan Aluminium is an industrial company that offers aluminum products, fabrication, and non-ferrous metal smelting services.
- Huaguan Biotechnology — Huaguan Biotechnology provides high-quality integrated drug research and development services for customers. This includes Sihuan Pharmaceutical, Sichuan Kelun, Tianjin Tasly, Beijing Yabao, Huasu Pharmaceutical, and other well-known domestic pharmaceutical companies, as well as Suzhou Amate, Shanghai Fuqi, Jiangsu Ya Sheng, and other scientificand technological innovation enterprises, the team development ability has been recognized by the industry and has attracted a number of listed companies such as Sihuan Pharmaceutical to inject capital.
Addor Capital offers investment services by financing early stage ventures and holding securities of other companies.
Show more...Investment focus
- Industry: Manufacturing, Semiconductor, Electronics
- Stage:Series A, Series B, Seed
- Geography: China, Hong Kong, Singapore
Investor stats
- Total investments: 321
- Round size: Seed $1.4k–$14M; Series A $1.4M–$28M; Series B $11M–$43M
- Lead/follow: 51% lead, 49% follow
Portfolio highlights
- Ibeki — Ibeki provides tiny photoelectric displacement sensors and servo control systems. eBridge uses the high precision and miniaturization of its precision motion drive technology to provide customers with a more complete technology portfolio, and has successfully transformed its core technology into a number of military and civilian products,particularly in aerospace, medical equipment, and intelligent control.
- Sichuan Ingia Biosynthetic — Looking for the best stevia manufacturers and wholesale suppliers? Look no further! Ingia Bio is the top natural sweetener manufacturer with a focus on precision fermentation. Find out why we're the best in the business!
- Wuxi Si-Power Micro-Electronics — Wuxi Si-Power Micro-Electronics is a developer and seller of power management integrated circuit products. Their products include AC/DC, DC/DC, and green power management chips used in smartphones, 5G communication adapters, small appliances, smart homes, smart meters, and automotive electronics fields.
UTEC-The University of Tokyo Edge Capital Partners Co., Ltd.. UTEC is a seed/early stage technology focused venture capital firm associated with The University of Tokyo.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A
- Geography: Japan, United States, India
Investor stats
- Total investments: 182
- Round size: Seed $3.1M–$48M; Series A $3.6M–$78M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- Flosfia — FLOSFIA is a spin-off from a research of Kyoto University, specializing in film-formation by mist chemical vapor deposition (CVD). Making use of physical properties of gallium oxide (Ga2O3), FLOSFIA has devoted to development of low-loss power devices.
- TXP Medical — TXP Medical build a next-generation medical system through acute care.
- Startbahn — Startbahn develops Startrail, a sustainable and scalable blockchain infrastructure that assures the reliability, authenticity, and traceability of artworks.
Beijing Huafang Investment focuses on the investment and management of state-owned capital and its investment covers commercial real estate.
Show more...Investment focus
- Industry: Biotechnology, Medical, Biopharma
- Stage:Series A, Seed, Angel
- Geography: China
Investor stats
- Total investments: 23
- Round size: Seed $13M–$14M; Series A $14M–$28M
- Lead/follow: 39% lead, 61% follow
Portfolio highlights
- Haimai Medical — Haimai Medical is a platform for tissue engineering and regenerative medicine technology. It focused on the development and manufacture of allogeneic small-caliber tissue-engineered blood vessels suitable for the establishment of chronic renal failure dialysis vascular access, lower extremity arterial trauma blood vessel replacement, lowerextremity atherosclerosis, and coronary heart disease bypass surgery.
- Westlake Therapeutics — Q1 2022 c-suite not found.
- Lingtai Krypton Biotechnology — Lingtai Krypton Biotechnology is an innovative corporation that specializes in the development of lncRNA drugs.
BioTrack Capital invests in early and growth stage companies within life sciences, healthcare technology, biotechnology and related high-tech sectors, providing capital and investment support for innovation. The firm evaluates scientific and commercial potential of ventures and structures financings aimed at advancing technologies from earlyresearch to market engagement. Its activities include sourcing opportunities, conducting due diligence, and working with founders and management teams to align growth strategies with investor objectives. BioTrack Capital also participates in funding rounds alongside co-investors to support development of novel healthcare and tech solutions. The company engages with portfolio companies through strategic interaction and monitoring of progress toward business milestones.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 89
- Round size: Seed $14M–$168M; Series A $14M–$45M; Series B $14M–$150M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- Taiyi Quantum — Taiyi Quantum is dedicated to encouraging innovation in the distribution and implementation of quantum computing technology, as well as developing sophisticated quantum algorithms and delivering tailored computing solutions for businesses and research institutes.
- Huihe Healthcare — Huihe Healthcare specializes in the development of medical devices for structural heart disease. The company was founded in 2019 and is headquartered in Shanghai, China.
- LaNova Medicines — LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Shunwei Capital is a venture capital fund that focuses on early to mid-stage investments in local internet industry. It specializes in incubation, startups, early to mid-stage, and growth capital investments. It seeks to invest in the technology, media, telecommunications, high technology, new media, games, internet finance, and rural area internetsectors. Their investors include sovereign wealth funds, fund of funds, university endowment funds, and family offices.
Show more...Investment focus
- Industry: Manufacturing, Software, Internet
- Stage:Series A, Series B, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 448
- Round size: Series A $1.4M–$43M; Series B $8.2M–$57M; Series C $20M–$100M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — raised $1.2B in 2018
Portfolio highlights
- CertiK — CertiK, the largest Web3 security service provider, uses AI and formal verification to protect and monitor smart contracts and protocols, securing the Web3 ecosystem.
- Z.ai — Z.ai develops artificial intelligence models and services built upon large-scale pretrained architectures. The company offers ChatGLM, a dialogue-focused language model series designed for smooth conversation and easy integration. It also provides Ying, a text-to-video model capable of generating short video clips from text or images, and AutoGLM,a voice-driven AI agent that performs smartphone tasks based on complex user instructions. Z.ai supports integration through an API platform and offers migration assistance for developers moving from other AI ecosystems. The company’s technology stems from research at Tsinghua University’s KEG lab and emphasizes general-purpose cognitive intelligence models.
- Darma — DARMA - Digital Healt
Lapam Capital is a healthcare-focused venture capital firm.
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Health Care
- Stage:Series A, Series B, Series C
- Geography: China, United States
Investor stats
- Total investments: 43
- Round size: Series A $13M–$40M; Series B $14M–$60M; Series C $14M–$100M
- Lead/follow: 40% lead, 60% follow
Portfolio highlights
- Degron Therapeutics — Degron Therapeutics is a leading platform company in discovery of molecular glue degraders for cancer treatment.
- NeuShen Therapeutics — We are a global biotech company committed to developing new and effective therapies for psychiatric and neurological disorders affecting millions of patients in need.
- Lingtai Biotechnology — Lingtai Biotechnology is a pharmaceutical and biotechnology based company that develops targeted protein degradation drugs.
Hillhouse Venture Capital is an investment institution established by Hillhouse Capital that focuses on investing in early-stage startups.
Show more...Investment focus
- Industry: Manufacturing, Biotechnology, Health Care
- Stage:Series A, Series B, Seed
- Geography: China, Singapore, Norway
Investor stats
- Total investments: 75
- Round size: Seed $10M–$120M; Series A $10M–$85M; Series B $14M–$99M
- Lead/follow: 44% lead, 56% follow
Portfolio highlights
- Yatsen Holding — Yasten provides high-quality fashion makeup products.
- RoboticPlus.AI — RoboticPlus.AI is an robtics company that helps in architectural tech by providing intelligent robotic products for the construction sector.
- kaye technology — Kaye Technology is a company that provides automation upgrade solutions for beverage equipment.
Legend Star helps entrepreneurs create great businesses through investments, CEO training sessions and an entrepreneurs alliance.Since 2008, Legend Star has incubated and invested in nearly 600 companies and is deeply integrated in the Chinese entrepreneurial ecosystem.Legend Star is the independent early-stage investment arm of LegendHoldings. Legend Holdings is the parent company of Lenovo, Raycom Real Estate, Joyvio Agribusiness and a large range of fast-growing Chinese companies.
Show more...Investment focus
- Industry: Health Care, Medical, Robotics
- Stage:Series A, Seed, Angel
- Geography: China, United States, France
Investor stats
- Total investments: 143
- Round size: Seed $1.4M–$19M; Angel $425k–$7.1M; Series A $1.4M–$112M
- Lead/follow: 24% lead, 76% follow
- Last fund: May invest from a new fund soon — raised $109M in 2018
Portfolio highlights
- Dongxi Fusion — Dongxi Fusion is an emerging energy technology promotion and technical service provider. The company is dedicated to providing technical services and advancing the adoption and deployment of new energy innovations.
- LifeLabs Design — LifeLabs patented warming & cooling technology allows for comfort across extreme temperatures. Explore our dedication to producing sustainable & eco-friendly fabrics.
- StarNuclear Fusion — StarNuclear Fusion is focused on the "high-temperature superconductivity + advanced quasi-isotropic propulsion (QI)" stellarator technology roadmap.
Keio Innovation Initiative (KII) is a venture capital established by Keio University. In order to make more effective use of the research results of Keio University, we aim to contribute to the development of society by creating investment for venture companies that utilize research results and creating new industries.The key to thinking aboutJapan's future growth strategy is to utilize advanced research results of the university. In addition to GDP, in addition to GDP, Japan is the world's third largest R & D exporter in R & D expenses, but as the low growth rate shows, it has a problem in investment efficiency in research and development. There are also reports on the entrepreneurial spirit that is indispensable for creating new industries, with the lowest entrepreneurial activity rate among developed countries.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Seed
- Geography: Japan, United Kingdom
Investor stats
- Total investments: 87
- Round size: Seed $1.5M–$57M; Series A $2.3M–$64M
- Lead/follow: 30% lead, 70% follow
- Last fund: May invest from a new fund soon — raised $1.4B in 2020
Portfolio highlights
- JiMED — JiMED designs & develops AI based brain-computer interface for implant in ALS patients to improve communication.
- Grafenary — Graphenary creates unique graphene optical devices using graphene materials with a variety of remarkable features.
- Neusignal Therapeutics — Neusignal Therapeutics is a medical company that develops therapeutic medicines for dementia and psychiatric illnesses.
Founded in 2009, Cowin Venture is an angel and early-stage investor in TMT and Healthcare. We keep nurturing growth-stage companies graduated from their angel investment portfolio. Cowin’s business network covers China and USA. They have offices in Suzhou, Nanjing, Shanghai, Beijing and Hong Kong.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Angel, Series B
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 100
- Round size: Angel $425k–$1.4M; Series A $1.4M–$25M; Series B $2.8M–$257M
- Lead/follow: 22% lead, 78% follow
Portfolio highlights
- CytoChip —
- Amador Bioscience — At Amador we provide global-standard translational sciences and clinical pharmacology services to leading biopharmaceutical companies.
- StringMotion Future — StringMotion Future focuses on the core technology research and development of tendon-inspired chord-driven robots, creating advanced robotic systems designed to deliver greater flexibility, precision, and efficiency for industrial and intelligent automation applications.
K2VC (Xianfeng Evergreen) was founded in 2010, focused on early stage investment in technology start-ups in China, focus on promoting change and technological progress, innovative business models and lifestyles.
Show more...Investment focus
- Industry: E-Commerce, Manufacturing, Biotechnology
- Stage:Series A, Seed, Angel
- Geography: China, United States, Japan
Investor stats
- Total investments: 191
- Round size: Seed $1M–$14M; Angel $425k–$10M; Series A $1.4M–$25M
- Lead/follow: 19% lead, 81% follow
- Last fund: May invest from a new fund soon — raised $141M in 2018
Portfolio highlights
- YolTech Therapeutics — Yaotang (Shanghai) Biotechnology is a high-tech biotechnology company focusing on developing a new generation of mRNA drugs and gene editing drugs by combining mRNA in vivo delivery technology and gene editing technology. Through the continuous development and optimization of CRISPR, base editing and other new-generation gene editing tools, andinnovative improvements to the next-generation mRNA production platform and lipid nanocarrier assembly process, Yaotang Bio is committed to developing treatments for genetic diseases and cardiovascular disease.
- Mofeng Technology — Mofeng Technology is a high-tech enterprise specializing in the research and development of polymer materials.
- ChipSense Technology — ChipSense Technology is a semiconductor focused on developing high-performance chips for AI computing infrastructure. The company provides chip solutions that enable perception and efficiency management in AI computing centers, helping optimize resource utilization, operational efficiency, and intelligent management of large-scale AI computingclusters.
Since its founding in 1973, JAFCO has always worked with leading-edge entrepreneurs. The total capital commitments of its investment funds in Japan and overseas have exceeded 1 trillion yen and the number of portfolio IPOs to date has reached over 1,000. In addition to venture investment, JAFCO also carries out buyout investment and commit to thecreations of innovative technologies and services worldwide. As entrepreneurs’ closest partner in bringing their visions to life, JAFCO provides support in areas of HR, marketing/ sales, and back-office operations, in addition to providing financing.
Show more...Investment focus
- Industry: Information Technology, Software, Artificial Intelligence
- Stage:Series A, Series B
- Geography: Japan, United States, Israel
Investor stats
- Total investments: 294
- Round size: Series A $1.9M–$170M; Series B $7M–$198M
- Lead/follow: 29% lead, 71% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- CaTe —
- Alxtal — Alxtal is a tech company who optimize the development, design, and manufacturing processes of the manufacturing industry with IT and AI.
- EISHIN — EISHIN is a technology company that specializes in pet tech business, recruitment consulting, website creation, and development services.
Shenzhen Oriental Fortune Capital Co Ltd. is a venture capital firm specializing investment in early venture, mid venture, late venture, emerging growth, Pre-IPO, mature, growth capital stage, mezzanine and new third board investments. The firm typically invests in financial services, telecommunication, new energy, consumer goods, medical treatmentand healthcare, life sciences, internet plus healthy lifestyle industry, logistics, energy technology, information technology, mobile innovation, media, movies and television, culture, pharmaceutical, biological medicine, renewable energy, retail, environmental protection business, consumption, new materials, new agriculture, advanced manufacturing, equipment manufacturing, culture, entertainment, and services. It seeks to invest in China focusing on Shenzhen, Shanghai, Beijing, Xi’an, and Wuhu. The firm also invests in Pearl River Delta region, Yangtze River Delta region, and Circum-Bohai-Sea region. For Pearl River Delta, it covers Guangzhou, Shenzhen, Foshan, Dongguan, Zhongshan, Zhuhai, Huizhou, Jiangmen, and Zhaoqing cities in China. For Yangtze River Delta, the firm covers Shanghai, Nanjing, Wuxi, Changzhou, Suzhou, Nantong, Yancheng, Yangzhou, Zhenjiang, Taizhou, Hangzhou, Ningbo, Jiaxing, Huzhou, Shaoxing, Jinhua, Zhoushan, Taizhou, Hefei, Wuhu, Ma’anshan, Tongling, Anqing, Chuzhou, Chizhou, and Xuancheng cities in China. For the Circum-Bohai-Sea region, it covers Beijing, Tianjin, Shenyang, Dalian, Qingdao, Dandong, Yingkou, Panjin, Fuxin, Huludao, Chaoyang, Shijiazhuang, Baoding, Tangshan, Qinhuangdao, Cangzhou, Langfang, Chengde, Zhangjiakou, Handan, Xingtai, Dongying, Yantai, Weifang, Weihai, Rizhao, and Binzhou cities in China. The firm prefers to invest 20% of its portfolio to early stage, 40% to expansion stage, and 40% to Pre-IPO stage. Shenzhen Oriental Fortune Capital Co Ltd. was formed in November 2007 and is based in Shenzhen, China with offices in Shanghai, China; Beijing, China; and Wuhu, China.
Show more...Investment focus
- Industry: Software, Manufacturing, Information Technology
- Stage:Series A, Series B, Seed
- Geography: China, United States
Investor stats
- Total investments: 251
- Round size: Seed $2.9M–$74M; Series A $1.4M–$50M; Series B $2.9M–$100M
- Lead/follow: 37% lead, 63% follow
- Last fund: May invest from a new fund soon — last raise in 2015
Portfolio highlights
- Xellar Biosystems — Xellar Biosystems is a wet artificial intelligence biotechnology company that provides analysis of drug testing and treatment.
- Qingyu Technology — Qingyu Technology is a software development service company specializing in the research, development, and sales of intelligent robots.
- Lightwheel — Light Wheel Intelligence is offers automated, physically precise and controllable, real and generalizable synthetic data solutions to build AI data infrastructure,
Sinovation Ventures is a full-service venture capital firm that actively invests in the Chinese technology market.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Internet
- Stage:Series A, Seed, Series B
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 256
- Round size: Seed $1M–$9M; Series A $1.4M–$28M; Series B $10M–$110M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely still investing — raised $203M in 2022
Portfolio highlights
- ChengRui — ChengRui is a green energy integrated solution providing company.
- Zhongke Yichuang — Zhongke Yichuang focuses on the development of automotive chips, power semiconductors and new energy vehicle controller systems.
- HPC-AI Technology — HPC-AI Technology provides a cloud-based platform to enhance AI computations by increasing CPU and GPU processing speeds.
FAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotech Investors in Asia investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 48,091 investors investing in Asia Biotech startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!